-- Scott Roberts
THURSDAY, Oct. 28 (HealthDay News) -- Lurasidone HCI (Latuda)
tablets have been approved by the U.S. Food and Drug Administration
to treat adult schizophrenia, which affects about 1 percent of the
nation's adult population in a given year, the agency said Thursday
in a news release.
The disorder's primary symptoms include hallucinations,
delusions, disordered behavior and suspiciousness, the agency said.
Among the most common hallucinations is hearing voices that other
people don't hear.
Latuda is an atypical antipsychotic drug. All medications in
this class contain a boxed label warning that prescribing them for
unapproved use in people with dementia-related psychosis increases
the risk of death. No atypical antipsychotic drug is sanctioned for
people with dementia-related psychosis, the agency warned.
Latuda was approved based on four six-week clinical studies of
adults with schizophrenia. Common adverse reactions included
drowsiness, restlessness, nausea, an uncontrolled urge to move
(akathisia), and movement disorders including tremors, muscle
stiffness and slow movement.
Latuda is produced by Sunovion Pharmaceuticals, based in Fort
The U.S. National Institute of Mental Health has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.